China-based biopharmaceutical company Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its category 1 innovative drug, chiauranib. The study will evaluate chiauranib in combination with a programmed-death (PD)-(ligand) 1 monoclonal antibody and chemotherapy as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC).
Dual-Action Mechanism of Chiauranib in Cancer Treatment
Chipscreen’s chiauranib is a highly selective small-molecule inhibitor targeting Aurora B, CSFR1, VEGFR/PDGR, and c-Kit. It works by inhibiting both angiogenesis and cell mitosis in cancer cells and regulating the tumor microenvironment. Chiauranib is effective against tumors with abnormal gene activity related to DNA replication and telomere maintenance by inhibiting the cell cycle regulatory kinase Aurora B or combining with other cell cycle suppressive chemotherapy drugs. This combination can create synthetic lethality, inhibiting tumor cell proliferation. Additionally, by inhibiting VEGFR and PDGFR, chiauranib can prevent tumor neovascularization, reducing tumor blood supply and growth. Inhibiting CSF1R and DDR also helps to suppress local immunosuppressive cells in tumors, enhancing the body’s immune surveillance and clearance function against tumors.
Ongoing Clinical Trials for Chiauranib
Chiauranib is currently in Phase III clinical studies in China for ovarian cancer in combination with chemotherapy and in Phase II studies for triple negative breast cancer, soft tissue sarcoma, and pancreatic cancer, either as a monotherapy or in combination with other drugs. The drug has completed Phase III clinical studies in SCLC as a monotherapy in China. Concurrently, Phase Ib/II studies for chiauranib as a monotherapy in SCLC/solid tumors are underway in the United States.- Flcube.com
